Genentech Announces Phase Iii Imscin001 Study Of Subcutaneous Formulation Of Tecentriq Meets Co Primary Endpoints
Genentech, A Member Of The Roche Group, Announced That The Phase Iii Imscin001 Study Evaluating A Subcutaneous Formulation Of Tecentriq (Atezolizumab) Met Its Co-Primary Endpoints. The Study Showed Non-Inferior Levels Of Tecentriq In The Blood (Pharmacokinetics), When Injected Subcutaneously, Compared With Intravenous (Iv) Infusion, In Cancer Immunotherapy-Na
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!